Levi & Korsinsky, LLP announces that an INSD class action lawsuit has been filed on behalf of investors who purchased Instadose Pharma Corp. f/k/a Mikrocoze, Inc.(INSD) securities between December 8, 2020, and November 24, 2021. For more on the INSD Lawsuit please contact us today.

According to the Instadose lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Instadose had performed inadequate due diligence into the business combination and/or ignored significant red flags associated with Instadose Canada; (ii) Instadose’s internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company; (iii) the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE INSD CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Instadose you have until February 28, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com